Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0145
0.00 (0.00%)
Mar 18, 2026, 9:30 AM EST
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $3.38M in the quarter ending September 30, 2025, a decrease of -38.34%. This brings the company's revenue in the last twelve months to $11.89M, down -41.78% year-over-year. In the year 2024, Emmaus Life Sciences had annual revenue of $16.65M, down -43.73%.
Revenue (ttm)
11.89M
Revenue Growth
-41.78%
P/S Ratio
0.09
Revenue / Employee
339.80K
Employees
35
Market Cap
1.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.65M | -12.94M | -43.73% |
| Dec 31, 2023 | 29.60M | 11.21M | 60.94% |
| Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
| Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
| Dec 31, 2020 | 23.17M | 415.00K | 1.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 20.18M |
| EV Biologics | 9.47M |
| International Stem Cell | 9.39M |
| Lyra Therapeutics | 600.00K |
| Lipella Pharmaceuticals | 389.78K |
| Eastgate Biotech | 137.64K |
| THC Farmaceuticals | 18.52K |
| Halberd | 6.94K |